NewsAvi Kapoor
Aclaris Therapeutics
ACRS · NASDAQ
$3.77+$0.29 (+8.33%)TodayMarket closed ·
Prev close $3.48
Latest news
- NewsAvi Kapoor
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsAvi Kapoor
Vipshop, Gorilla Technology Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- NewsAvi Kapoor
Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- Press releaseGlobe Newswire
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- News
Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways
- Press releaseGlobe Newswire
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- NewsRishabh Mishra
Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
- Press releaseGlobe Newswire
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
- Press releaseGlobe Newswire
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsVandana Singh
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
- Press releasePRNewswire
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
- Press releaseGlobe Newswire
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.